

## 4.0.03 DOC Cmte minutes

### Colorectal Cancer (CRC) (update) Committee meeting 4

**Date:** 29<sup>th</sup> March 2018

**Location:** RCOG, London

**Minutes:** Confirmed

<b>Committee members present:</b>		
Peter Hoskin, Chair ( <b>PH</b> )		(Present for notes 1–8)
Justin Davies ( <b>JD</b> )		(Present for notes 1–8)
Stephen Fenwick ( <b>SF</b> )		(Present for notes 1–8)
Baljit Singh ( <b>BS</b> )		(Present for notes 1–8)
Julie Hepburn ( <b>JH</b> )		(Present for notes 1–8)
Debby Lennard ( <b>DL</b> )		(Present for notes 1–8)
Vivek Misra ( <b>VM</b> )		(Present for notes 1–8)
Charlotte Dawson ( <b>CD</b> )		(Present for notes 1–8)
Michael Braun ( <b>MB</b> )		(Present for notes 1–8)
Jay Bradbury ( <b>JB</b> )		(Present for notes 1–8)
Richard Roope ( <b>RR</b> )		(Present for notes 1–8)

<b>In attendance:</b>		
Matthew Prettyjohns ( <b>MP</b> )	NGA Guideline Lead	(Present for notes 1–8)
Michaela Dijmarescu ( <b>MD</b> )	NGA Project Manager	(Present for notes 1–8)
Maija Kalioinen ( <b>MK</b> )	NGA Systematic Reviewer	(Present for notes 1–8)
Nathan Bromham ( <b>NB</b> ) <i>via VC</i>	NGA Senior Systematic Reviewer	(Present for notes 1–8)
Audrey Tan ( <b>AT</b> )	NGA Systematic Reviewer	(Present for notes 1–8)
John Graham ( <b>JG</b> )	NGA Clinical Advisor	(Present for notes 1–8)

<b>Observers:</b>	
None	

#### 4.0.03 DOC Cmte minutes

<b>Apologies:</b>	
Kevin Monahan ( <b>KM</b> )	Full Committee Member
Gemma Burgess ( <b>GB</b> )	Co-opted Committee Member
Justine Karpusheff ( <b>JK</b> )	NICE Guideline Commissioning Manager

#### 1. Welcome, housekeeping, aims of the day and apologies

The Chair welcomed the committee members to the 4th meeting for the colorectal cancer (CRC) guideline update.

The Chair informed the Committee that apologies had been received as noted above.

The Chair outlined the objectives of the meeting, which included:

- Presentations of evidence for review questions 3.1 and 3.4;
- Protocols signed off by the committee (3.9, 4.2 and 4.3 resectable and unresectable disease)

The minutes of the 3<sup>rd</sup> colorectal cancer guideline committee meeting were confirmed with the Committee.

The Chair led round the table introductions for the group. The Chair confirmed that, for the purpose of managing conflicts of interest, the matter under discussion was colorectal cancer.

The Chair asked everyone to verbally declare any interests. The Chair made a note about the participation of committee members who have declared private practice.

There were declarations of interest included in the table below.

<b>Name</b>	<b>Job title, organisation</b>	<b>Declarations of Interest</b>	<b>Type of interest</b>	<b>Decision taken</b>
Peter Hoskin	Consultant in Clinical Oncology, Mount Vernon Hospital, Northwood, Middlesex	Appointed member of NIHR bladder and renal clinical studies group 04/04/2018	Personal non-financial, non-specific	Declare and participate
Justin Davies	Consultant Colorectal Surgeon, Cambridge Colorectal Unit, Addenbrooke's Hospital, Cambridge	Publications from membership of international pelvic exenteration collaborative (Pelvex) Pelvex Collaborative. Surgical and survival outcomes following	Personal, non-financial, specific	Declare and participate

#### 4.0.03 DOC Cmte minutes

		pelvic exenteration for locally advanced rectal cancer: Results from an international collaboration <i>Annals of Surgery</i> 2017 Sep 21. doi: 10.1097/SLA.0000000002528. [Epub ahead of print 04/04/2018		
Justin Davies	Consultant Colorectal Surgeon, Cambridge Colorectal Unit, Addenbrooke's Hospital, Cambridge	Pelvex Collaborative. Factors affecting the outcomes following pelvic exenteration for locally recurrent rectal cancer: Results from an international collaboration <i>British Journal of Surgery</i> 2018 Mar 12. doi: 10.1002/bjs.10734. [Epub ahead of print] 04/04/2018	Personal, non-financial, specific	Declare and participate
Justin Davies	Consultant Colorectal Surgeon, Cambridge Colorectal Unit, Addenbrooke's Hospital, Cambridge	Xanthis A, Greenberg D, Miller R, Fearnhead N, <b>Davies R J</b> , Hall N. Local recurrence after 'standard' abdominoperineal resection: do we really need ELAPE? <i>Annals of The Royal College of Surgeons of England</i> 2017; (in press) 04/04/2018	Personal, non-financial, specific	Declare and participate
<b>2. Update on protocols 3.6, 3.7 and 4.1</b>				
The Chair introduced Maija Kalionen (NGA Systematic Reviewer) who discussed with the committee protocols 3.6, 3.7 and 4.1 and finalised them.				
<b>3. Review 3.1 What is the most effective treatment for early rectal cancer?</b>				
The Chair introduced Audrey Tan (NGA Systematic Reviewer) who presented the evidence review for question 3.1 (What is the most effective treatment for early rectal cancer?) and took				

#### 4.0.03 DOC Cmte minutes

questions from the committee.

The Chair led a discussion with the committee and recommendations were drafted for review question 3.1.

#### **4. Review 3.4 What is the effectiveness of preoperative radiotherapy or chemoradiotherapy for rectal cancer?**

The Chair introduced Maija Kalioinen (NGA Systematic Reviewer) who presented the evidence review for question 3.4 (What is the effectiveness of preoperative radiotherapy or chemotherapy for rectal cancer?) and took questions from the committee.

The Chair led a discussion with the committee and recommendations were drafted for review question 3.4.

#### **5. Develop protocol for review question 3.9 What is the effectiveness of exenterative surgery for locally advanced or recurrent rectal cancer?**

The Chair introduced Maija Kalioinen (NGA Systematic Reviewer) who presented the protocol for review question 3.9 and finalised it with the Committee.

#### **6. Develop protocol for review question 4.3.b What is the optimal combination and sequence of local, loco-regional and systemic treatments in patients presenting with oligometastatic colorectal cancer in the liver (resectable and unresectable disease)?**

The Chair introduced Audrey Tan (NGA Systematic Reviewer) who presented the protocol for review question 4.3 b and finalised it with the Committee.

#### **7-8. Develop protocol for review question 4.2 Does surgery for the asymptomatic primary tumour improve outcomes for people with incurable metastatic colorectal cancer?**

The Chair introduced Audrey Tan (NGA Systematic Reviewer) who presented the protocol for review question 4.2 and finalised it with the Committee.

#### **9. Any other business**

Matthew Prettyjohns (NGA Guideline Lead/ Senior Health Economist) updated the committee with regards to the submitted development time request and timelines.

The Committee reviewed the recommendations edited by the NICE Editor for review 1.1 (How effective is aspirin in the prevention of colorectal cancer in adults with Lynch syndrome (hereditary nonpolyposis colorectal cancer)?).

#### **10. Close of meeting**

The Chair thanked the Committee and reminded them that the next meeting would be held on the 03<sup>rd</sup> May 2018 at the RCOG, London and closed the 4th guideline committee meeting for the NICE Colorectal Cancer (update) guideline.

#### **4.0.03 DOC Cmte minutes**

**Date of next meeting:** 03<sup>rd</sup> May 2018

**Location of next meeting:** RCOG, London